| Identification | Back Directory | [Name]
Benzonitrile, 4-[3-[4-[(2S)-2,3-dihydroxypropoxy]phenyl]-4,4-dimethyl-5-oxo-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)- | [CAS]
1572045-62-5 | [Synonyms]
SHR3680
Rezvilutamide
Benzonitrile, 4-[3-[4-[(2S)-2,3-dihydroxypropoxy]phenyl]-4,4-dimethyl-5-oxo-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)- | [Molecular Formula]
C22H20F3N3O4S | [MOL File]
1572045-62-5.mol | [Molecular Weight]
479.47 |
| Chemical Properties | Back Directory | [Boiling point ]
648.3±65.0 °C(Predicted) | [density ]
1.50±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 100 mg/mL (208.56 mM; Need ultrasonic) | [form ]
Solid | [pka]
13.42±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Rezvilutamide (SHR3680) is an orally active androgen receptor antagonist. Rezvilutamide (SHR3680) is used for the study of prostate cancer[1][2]. | [References]
[1] SangjunYoo, et al. New drugs in prostate cancer. Prostate International Volume 4, Issue 2, June 2016, Pages 37-42.
[2] Veronica Mollica, et al. Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer. Cells. 2019 Jan 11;8(1):43. DOI:10.3390/cells8010043
[3] Dai T, et al., A single-centre, open-label, single-arm, fixed-sequence pharmacokinetic study of SHR3680 on repaglinide and bupropion in prostate cancer patients. Br J Clin Pharmacol. 2023 Feb;89(2):874-886. DOI:10.1111/bcp.15528 |
|
|